MarketCap
Facebook
X
TelegramAnnual report 2025
added 03-11-2026
Evofem Biosciences Long-Term Debt 2011-2026 | EVFM
Long-term debt is a financial obligation of a company or an individual with a repayment period exceeding one year from the date it arises. In accounting, such obligations are recorded under the "long-term liabilities" section.
Main characteristics:- Term exceeds 12 months
- Can take the form of bonds, bank loans, credit lines, leasing, or loans from affiliated parties
- Repaid through regular payments (interest and/or principal) over several years
- Investment in development
Allows financing of large projects — new factories, production lines, innovative developments — without diverting working capital. - Smoothing of cash flows
A long-term payment schedule facilitates budget planning and reduces short-term financial risks. - Optimization of capital structure
A combination of equity and borrowed capital can reduce the average cost of business financing.
A high level of long-term debt may indicate that a company heavily relies on borrowed funds. This increases risks, especially in conditions of rising interest rates or declining profits. However, a moderate level of debt can signal a sound growth strategy — for example, the company takes a loan to expand its business.
If a company uses borrowed funds effectively (e.g., invests in profitable projects), this can lead to profit growth and, consequently, an increase in stock value. An investor evaluates whether the investments made using debt are paying off.
It is important to monitor whether the company can regularly pay interest and repay the principal. Payment difficulties can lead to reduced dividends, a drop in stock value, and even bankruptcy.
Examples of long-term debt:- Mortgage loans for property purchases
- Corporate bonds issued by a company to raise capital
- Project financing — long-term loans for building or expanding production facilities
- Leasing obligations for equipment or transport
Annual Long-Term Debt Evofem Biosciences
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 54 K | 7 K | 8 K | 3.13 M | 4.42 M | 25.2 M | - | - | - | - | 7.21 M | 9.74 M | - | - | - |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 25.2 M | 7 K | 6.22 M |
Quarterly Long-Term Debt Evofem Biosciences
| 2025-Q3 | 2025-Q2 | 2025-Q1 | 2024-Q4 | 2024-Q3 | 2024-Q2 | 2024-Q1 | 2023-Q4 | 2023-Q3 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 72 K | 89 K | 5 K | 7 K | 10 K | 1 K | 4 K | 8 K | 13 K | 22 K | 2.63 M | 3.13 M | 3.62 M | 3.91 M | 4.06 M | 4.42 M | 26.7 M | 26.2 M | 25.7 M | 25.2 M | 25.2 M | 25.2 M | 25.2 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 2.81 M | 3.15 M | 7.21 M | 7.21 M | 7.21 M | 7.21 M | 9.74 M | 9.74 M | 9.74 M | 9.74 M | - | - | - | - | - | - | - | - | - | - | - | - |
All numbers in USD currency
Indicator range from quarterly reporting
| Maximum | Minimum | Average |
|---|---|---|
| 26.7 M | 1 K | 8.34 M |
Long-Term Debt of other stocks in the Biotechnology industry
| Issuer | Long-Term Debt | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
 |
MorphoSys AG
MOR
|
273 M | - | 2.43 % | $ 254 M |  Germany |
 |
Grifols, S.A.
GRFS
|
5.9 B | $ 8.24 | -0.12 % | $ 6.83 B |  Spain |
 |
I-Mab
IMAB
|
68.2 M | - | - | $ 866 M |  China |
 |
Alexion Pharmaceuticals, Inc.
ALXN
|
2.42 B | - | - | $ 40.3 B |  USA |
 |
Genfit SA
GNFT
|
173 M | - | 2.54 % | $ 160 B |  France |
 |
Biophytis SA
BPTS
|
1.83 M | - | -13.47 % | $ 169 M | France |
 |
Midatech Pharma plc
MTP
|
4.76 M | - | -18.52 % | $ 27.3 M |  Britain |
 |
EyeGate Pharmaceuticals, Inc.
EYEG
|
278 K | - | -1.52 % | $ 24.7 M | USA |
 |
AbbVie
ABBV
|
64.5 B | $ 208.84 | -2.86 % | $ 369 B | USA |
 |
AbCellera Biologics
ABCL
|
137 M | $ 3.52 | 0.28 % | $ 1.05 B |  Canada |
 |
Acorda Therapeutics
ACOR
|
167 M | - | -24.86 % | $ 820 K | USA |
 |
Adverum Biotechnologies
ADVM
|
86 M | - | - | $ 86.2 M | USA |
 |
Advaxis
ADXS
|
8.14 M | - | -9.65 % | $ 45.9 M | USA |
 |
Applied Molecular Transport
AMTI
|
49 K | - | - | $ 10.1 M | USA |
 |
Aeterna Zentaris
AEZS
|
31 K | - | 5.93 % | $ 314 M | Canada |
 |
AgeX Therapeutics
AGE
|
2.95 M | - | -10.17 % | $ 12.2 K | USA |
 |
AIkido Pharma
AIKI
|
2.29 M | - | 1.93 % | $ 17.4 M | USA |
 |
Agenus
AGEN
|
30.5 M | $ 3.33 | -2.06 % | $ 99 M | USA |
 |
Aeglea BioTherapeutics
AGLE
|
4 M | - | - | $ 1.01 B | USA |
 |
Applied Genetic Technologies Corporation
AGTC
|
9.12 M | - | - | $ 26.5 M | USA |
 |
Akero Therapeutics
AKRO
|
529 K | - | - | $ 3.67 B | USA |
 |
Akouos
AKUS
|
28.3 M | - | 0.23 % | $ 488 M | USA |
 |
Институт стволовых клеток человека
ISKJ
|
175 M | - | - | - |  Russia |
 |
Allena Pharmaceuticals
ALNA
|
210 K | - | 3.16 % | $ 1.9 M | USA |
 |
Alpine Immune Sciences
ALPN
|
3.38 M | - | - | $ 2.17 B | USA |
 |
Aileron Therapeutics
ALRN
|
69 K | - | 10.36 % | $ 9.8 M | USA |
 |
Adaptive Biotechnologies Corporation
ADPT
|
127 M | $ 14.81 | 2.63 % | $ 2.25 B | USA |
 |
Altimmune
ALT
|
34.3 M | $ 3.34 | 7.05 % | $ 294 M | USA |
 |
BioNTech SE
BNTX
|
231 M | $ 91.18 | 1.97 % | $ 27.2 B | Germany |
 |
Amgen
AMGN
|
50 B | $ 347.94 | -1.51 % | $ 187 B | USA |
 |
ANI Pharmaceuticals
ANIP
|
309 M | $ 74.21 | -2.3 % | $ 1.43 B | USA |
 |
Aravive
ARAV
|
1.88 M | - | -13.39 % | $ 1.45 M | USA |
 |
Arcturus Therapeutics Holdings
ARCT
|
20.8 M | $ 8.03 | 2.29 % | $ 220 M |  Israel |
 |
Aptose Biosciences
APTO
|
193 K | - | -45.71 % | $ 1.2 M | Canada |
 |
Aurinia Pharmaceuticals
AUPH
|
52.3 M | $ 15.61 | 0.9 % | $ 2.1 B | Canada |
 |
Autolus Therapeutics plc
AUTL
|
66.8 M | $ 1.41 | 2.17 % | $ 375 M | Britain |
 |
Aptinyx
APTX
|
22.1 M | - | -39.0 % | $ 4.57 M | USA |
 |
Aytu BioScience
AYTU
|
10.9 M | $ 2.68 | 1.52 % | $ 16.8 M | USA |
 |
CureVac N.V.
CVAC
|
25.4 M | - | - | $ 867 M | Germany |
 |
AstraZeneca PLC
AZN
|
17.5 B | - | - | $ 96.9 B | Britain |
 |
Avenue Therapeutics
ATXI
|
2.03 M | - | -52.27 % | $ 4.45 M | USA |
 |
Atea Pharmaceuticals
AVIR
|
842 K | $ 5.76 | 1.95 % | $ 469 M | USA |
 |
AVROBIO
AVRO
|
188 K | - | 1083.1 % | $ 745 M | USA |
 |
BioCryst Pharmaceuticals
BCRX
|
315 M | $ 9.02 | -3.84 % | $ 1.86 B | USA |
 |
Axcella Health
AXLA
|
25.1 M | - | -16.42 % | $ 249 M | USA |
 |
Axon Enterprise
AXON
|
41.4 M | $ 412.81 | -2.54 % | $ 31.3 B | USA |
 |
Alnylam Pharmaceuticals
ALNY
|
1.01 B | $ 318.85 | -3.01 % | $ 41.8 B | USA |
 |
Ayala Pharmaceuticals
AYLA
|
1.33 M | - | - | $ 7.46 M | Israel |